Edo Kiper

Edo Kiper

Auto-generated profile, based on publicly available information

Edo Kiper

Department of Biomolecular Sciences, Faculty of Biochemistry Weizmann Institute of Science Rehovot Israel

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
NENadav Elkoshi
Nadav Elkoshi
SPShivang Parikh
Shivang Parikh
HMHagar Malcov-Brog
Hagar Malcov-Brog
RPRoma Parikh
Roma Parikh
PMPaulee Manich
Paulee Manich
CLCarmit Levy
Carmit Levy

6 August 2025 in Journal of Peptide Science
Verified
Journal Article
Open access
Bruno CasciaroBruno Casciaro
Bruno Casciaro
DHDaniel Ben Hur
Daniel Ben Hur
DRDaniela Roversi
Daniela Roversi
CVCarlo Vetrano
Carlo Vetrano
EKEdo Kiper
Edo Kiper
Maria Luisa MangoniMaria Luisa Mangoni
Maria Luisa Mangoni
Antimicrobial peptides (AMPs) represent valid alternatives to conventional antibiotics primarily due to their mechanism of action, which consists of cytoplasmic membrane disruption. However, their clinical application is often limited by cytotoxicity at high concentrations and low intrinsic biostability. To address these limitations, various biochemical approaches have been explored. In recent years, the frog‐skin derived AMP Esc(1‐21) has been extensively characterized for its potent antimicrobial activity, especially against Gram‐negative bacteria, both in vitro and in vivo. In this study, we designed and synthesized novel Esc(1‐21) analogs in which a single isopeptide bond was introduced in place of a conventional peptide bond at specific positions within the sequence. The resulting five analogs were evaluated for their (i) chemical and structural properties, (ii) resistance to proteolytic degradation, (iii) antimicrobial and antibiofilm activities, (iv) hemolytic and cytotoxic effects, and (v) ability to perturb bacterial cytoplasmic membranes. Among these, Esc(1‐21)ε20 showed the most promising features, maintaining antimicrobial and antibiofilm activities comparable to those of the parent peptide while exhibiting lower cytotoxicity towards eukaryotic cells at higher concentrations and greater resistance to enzymatic degradation. These findings highlight Esc(1‐21)ε20 as an attractive lead candidate for the development of new antibiotic therapeutics.